Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 [BG 12] in Subjects With Relapsing-Remitting Multiple Sclerosis

Trial Profile

Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 [BG 12] in Subjects With Relapsing-Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Biogen Idec
  • Most Recent Events

    • 28 Oct 2017 Results (Data cut of 1 October 2016; n=2513) of integrated analysis of DEFINE, CONFIRM, ENDORSE and NCT00168701 trials assessing the dynamics and clinical implications of on-DMF absolute lymphocyte count decline and post-DMF absolute lymphocyte count reconstitution presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Apr 2017 Results of an integrated analysis (n=2470) of phase III (DEFINE, CONFIRM and ENDORSE-extension) and phase IIb Dimethyl Fumarate (DMF) studies reporting long-term absolute lymphocyte count (ALC) and post-DMF ALC data, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 25 Oct 2008 Results have been published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top